Ligand Pharmaceuticals (LGND) Q4 2024 earnings summary

Executive summary

• Achieved strong financial and operational performance in 2024, with total revenue up 27% to $167.1 million and royalty revenue growth of 28%, driven by new product approvals and portfolio expansion including Ohtuvayre, Capvaxive, ZELSUVMI, and Qarziba.

• Transformed into a profitable, infrastructure-light, and economically diversified organization, focusing on high-value royalty assets and scalable growth.

• Generated over $100 million in cash from operations, ending 2024 with $256 million in cash and investments and no debt.

• Strategic investments and disciplined capital allocation, including a $50 million investment in Castle Creek's D-Fi and a $75 million syndicated round, further diversified the portfolio.

• Anticipates multiple milestones in 2025, including a potential strategic transaction and ZELSUVMI launch.

Financial highlights

• Total 2024 revenue grew 27% year-over-year to $167.1 million; royalty revenue increased 28% to $108.8 million.

• Q4 2024 revenue rose 52% to $42.8 million, with royalties up 55% to $34.8 million compared to Q4 2023.

• Core adjusted EPS increased over 40% year-over-year to $5.74; adjusted net income (excluding Viking stock gains) was $108.5 million.

• Ended 2024 with $256 million in cash and investments, no debt, and access to a $125 million credit facility (expandable to $175 million).

• Full year 2024 GAAP net loss was $4 million, driven by non-cash items including asset impairment and fair value adjustments.

Outlook and guidance

• 2025 royalty revenue expected between $135 million-$140 million; total revenue guidance of $180 million-$200 million.

• Adjusted EPS forecast for 2025 is $6.00-$6.25.

• Long-term royalty receipts projected to grow at a 22%+ CAGR from 2024 through 2029.

• Commercial portfolio expected to drive mid-teens growth through early 2030s, with EPS growth above 20% when including development-stage assets.

• Anticipates ZELSUVMI launch by mid-2025 and multiple value-creating milestones.